.Pharmacolibrary.Drugs.ATC.J.J05AX31 .Pharmacolibrary.Drugs.ATC.J.J05AX31| name: | Lenacapavir |
| ATC code: | J05AX31 | route: | subcutaneous |
| n-compartments | 2 |
Lenacapavir is a first-in-class long-acting capsid inhibitor used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are heavily treatment-experienced. It works by inhibiting the HIV-1 capsid protein, thereby disrupting multiple steps of the viral life cycle. Lenacapavir is approved for use in the United States and European Union.
Pharmacokinetic parameters reported in healthy adult volunteers, after subcutaneous administration.
Jogiraju, V, et al., & Singh, R (2025). Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. Lancet (London, England) 405(10485) 1147–1154. DOI:10.1016/S0140-6736(25)00405-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40086460
Marzolini, C, et al., & Khoo, S (2025). Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir. Expert opinion on drug metabolism & toxicology 21(2) 161–172. DOI:10.1080/17425255.2024.2415295 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39411777
Beran, C, et al., & Sahloff, EG (2024). A Narrative Review of Novel Agents for Managing Heavily Treatment-Experienced People Living With HIV. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians 40(4) 194–201. DOI:10.1177/87551225241259894 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39157636